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Abstract| It is becoming increasingly apparent that microglia, the immune cells of the CNS, and their peripheral 
counterparts, macrophages, have a major role in normal physiology and pathology. Recent technological advances 
in the production of particular cell types from induced pluripotent stem cells (iPSCs) have led to an interest in applying 
this methodology to the production of microglia. Here we will discuss recent advances in this area and describe how 
they will aid our future understanding of microglia. 
 
[H1] Introduction 
Both microglia and macrophages have been increasingly recognized for their significant roles in brain function. Under 
physiological conditions, microglia are exquisite sensors of changes in their micro-environments, detecting infection 
or damage and responding by migrating, proliferating, phagocytosing or producing cytokines and neurotrophins to 
protect, defend, and maintain a homeostatic environment1 (Fig. 1). Such responses are also observed in a wide range 
of neurodegenerative conditions (Fig. 1) as well as in acute conditions such as stroke; however in these instances, 
the microglial response may become dysregulated and chronic2. In certain conditions, monocyte-derived 
macrophages that are usually restricted to the periphery are thought to enter the brain, where they have been shown 
to be capable of assuming a microglial-like phenotype3,4.  
 
A number of factors have pushed microglia into the forefront of neuroscience research in recent years. These include 
the growing appreciation of the role of these cells in the development of neurological conditions, particularly dementia 
(an escalating societal and economic problem in western society, with an urgent need for therapeutics) and the 
findings of recent human genetic studies (and in particular of genome-wide association studies (GWAS) and whole 
genome sequencing studies) that have highlighted a clear genetic link between dementia and inflammation5,6,7. In 
addition, the well-established role of neuroinflammation in multiple sclerosis8 as well as increasing evidence for its 
role in other neurodegenerative diseases, including Parkinson disease, Alzheimer disease and amyotrophic lateral 
sclerosis9,10,11 have helped to drive an increasing focus on microglia.  
 
The lack of successful disease-modifying therapeutic developments in neurological diseases has brought into 
question the capacity of animal models to recapitulate the human condition12,13. This, coupled with a growing 
opposition in western society to the use of animals in research because of ethical and welfare concerns14, has led to 
the search for better ‘humanised’ models of neurological function and disease. The use of ‘primary’ human tissue 
provides one possible solution; however, this material is often derived from contentious sources, including foetal 
tissues, that also raise ethical concerns. In addition, although primary tissue is highly informative and vital for ongoing 
research, issues including post-mortem artefacts, the influence of underlying diseases (such as epilepsy) present in 
the individuals from whom the tissue is derived and the obvious difficulties in obtaining sufficient study material 
invalidate this as a source of material for long term mechanistic studies of the early physiological changes that occur 
in neurological diseases.  
 These caveats have led to the development of approaches for the long-term culture of human cells. These have 
included the generation of microglial-like models directly from human monocytes15,16 and a number of cell biology 
companies have been established that specialize in the production of such cells. However, due to the rarity of many 
of the genetic risk factors associated with neurodegenerative diseases, cells from these sources are unlikely to 
express the single-nucleotide polymorphisms or mutations that would enable targeted studies of these diseases. 
These risk factors can of course be introduced by new genome editing technologies; however, to study the mutations 
in the context of disease it is necessary to acquire cells directly from a patient.  
 
To address these concerns, recent advances in iPSC methodologies that were initially developed to generate 
primitive and definitive hematopoietic cells and neurons17,18 are now being applied to the production of macrophages 
and microglia. The advantages of this approach include the ability to produce large numbers of human-derived cells 
with an adult phenotype that is very difficult to obtain through traditional methods and the provision of a source of 
cells expressing particular genetic mutations linked to disease, allowing in depth disease-relevant study of 
pathological mechanisms. This is especially advantageous when the number of patients expressing these gene 
mutations are very rare, as is the case for the variants in the genes encoding receptors such as triggering receptor 
expressed on myeloid cells 2 (TREM2) that are linked to increased risk of developing late onset Alzheimer disease5,7. 
 
These advances may enable future production of ‘disease in a dish’ models, which may allow us to better understand 
the consequences of genetic predisposition to dementias and other chronic neurological diseases in which microglia 
are thought to play a role. The sophistication of these models can be altered depending on the users’ needs. Cells 
can be derived in isolation or new culturing techniques, including organoid development, can be utilised to allow users 
to introduce microglia or microglial precursors into three dimensional tissues of neurons, astrocytes and 
oligodendrocytes (all with controlled phenotypes) to investigate cell autonomous and non-cell autonomous 
responses. These cells can also be used to inform us of changes in the physiology of human microglia in the healthy 
nervous system during development and in genetic-associated diseases.  
 
In this article we will discuss the properties of microglia generated from iPSCs and consider the advantages and 
caveats of such models. To provide context to the history iPSC-derived microglia methodologies, we shall also briefly 
discuss the generation of iPSC-derived macrophages.  
 
[H1] Protocols and phenotypes  
 
A number of methods for the generation of iPSC-derived microglia-like or macrophage-like cells from both human 
and rodent tissue have been published in the last five years (Table 1). These methods have allowed large numbers 
of cells to be produced and, in general, the phenotype of these cells has been described as being similar either to 
that of peripheral blood monocyte (PBM)-derived macrophages or to that of tissue resident macrophages and CNS-
localised microglia. To date, all published protocols follow a similar path, based largely on cellular ontogeny. Donor 
cells are initially de-differentiated to produce iPSCs. These cells are then supplemented with growth factors 
associated with mesodermal specification, leading to the development of hemangioblasts and primitive hematopoietic 
progenitors, and this is followed by continued maturation along the myeloid lineage with further growth factor cocktails.  
 A number of established protocols can produce microglia-like cells from human monocytes. However, the use of 
monocyte-derived microglia as a human model of CNS microglia remains contentious because of the differences in 
the proposed origins of CNS microglia from those of peripheral macrophages in vivo. Microglia are thought to be 
erythromyeloid progenitor (EMP)-derived, arising from the yolk-sac19,20, whereas PBM-derived macrophages arise 
from circulating bone marrow-derived cells21. However, tissue-resident macrophages, including the Langerhans cells 
of the skin, alveolar macrophages of the lung and Kupffer cells of the liver22, are also derived from EMPs. These cells 
therefore do not have a monocytic progenitor and are maintained independently of the bone marrow, like 
microglia19,23,24 . Furthermore, it has been shown that microglia and tissue-resident macrophages, but not PBM-
derived macrophages, are derived from precursors whose development depends on the transcription factors PU.1 
and runt-related transcription factor 1 (RUNX1) but does not require the transcriptional activator MYB, indicating 
different embryonic sources of these cells19,20,25,26. Such discoveries have enabled researchers to refine iPSC-derived 
models to generate the cell-specific progenitors required for the development of true microglial-like cells. This allows 
for more phenotypically accurate studies, potentially more translatable to in vivo conditions.  
 
There is considerable debate in the literature about what certain iPSC microglial differentiation protocols actually 
produce in terms of their phenotype. Recent advances in iPSC methodologies have found that a microglial-like 
phenotype can be induced by incubation of human iPSC-derived microglial and/or macrophage progenitors with 
various combinations of factors: these include high levels of colony-stimulating factor 1 (CSF1) and interleukin 34 (IL-
34)27; IL-34 and granulocyte macrophage colony-stimulating factor (GM-CSF)28; IL-3, IL-34, and GM-CSF29, and IL34, 
CSF1, transforming growth factor-β (TGFβ1), fractalkine (CX3CL1) and CD20030. These protocols are able to 
generate cells that exhibit similar gene expression patterns to those of human primary microglia28,30 , express known 
microglial markers27,28,29,30, perform microglial functions (including phagocytosis and secretion of cytokines)27,28,29,30 
and respond to ADP or ATP via P2Y purinoceptor 12 (P2RY12) to produce intracellular calcium transients28,30.  
 
Despite the phenotypic similarities between these iPSC-derived cells and endogenous microglia, the laboratories 
responsible for their production and others have questioned the simplicity of such models and have provided evidence 
that more complex culture conditions are necessary for the generation of more authentic models of microglia29,30,31,32. 
Indeed, some prescribe the use of neuronal co-cultures to further enhance the microglial ‘signature’ — that is, the 
gene expression, cytokine release in response to stimulants, phenotypic responses to exogenous or endogenous 
insults and cellular morphology — of their generated cells27,30,31,32. Although a number of the recently published 
protocols provide strong phenotypic evidence for the production of microglial-like cells, it is clear that there is not yet 
a definitive method for the production of a completely satisfactory microglial phenotype from iPSCs and that such a 
protocol is a work in progress.  
 
The protocols described above differ from those used for the production of macrophages from human iPSCs, in which 
the use of macrophage/monocyte colony-stimulating factor (M-CSF) and IL-3 have been used33,34. In the presence of 
M-CSF alone, human iPSCs generated cells with phenotypes that resemble those of anti-inflammatory, regenerative 
‘M2-type’ macrophages, including long filopodia, large intracellular vacuoles and the expression of classical 
macrophage markers such as CD45, CD14, CD163 and CD8634. These cells were also able to phagocytose latex 
beads and produce a number of cytokines in response to lipopolysaccharide, including tumour necrosis factor α (TNF-
), monocyte chemoattractant protein 1, IL-6, IL-8 and IL-1034. The ability to secrete IL-6 does, however, suggest that 
these cells consisted of a somewhat mixed phenotype, because this cytokine has been found to be secreted by 
inflammatory ‘M1-type’ macrophages and M2-type macrophages35. The high level of TNF secretion by iPSC-derived 
macrophages is also similar to PBM-derived M1-type macrophages34. One possibility, which should be explored, is 
that there may be an influence of priming on these findings: that is, pre-exposure to a stimulus, such as serum factors 
in undefined media compositions, may convert the cells into an alerted, activated state as described by the M1/2 
classification. It may therefore be necessary to mature the cells for longer in culture in order to ensure that they are 
in a more down-regulated state, similar to that found in vivo. 
 
[H1] Microglia or macrophages? 
 
The variations in protocol and phenotype reported by the studies described above raise an important question: what 
defines an iPSC-derived microglial cell and separates this from an iPSC-derived tissue-resident macrophage or 
monocyte-derived macrophage?  
 
Recent transcriptomic studies of the differences between human iPSC-derived microglia and PBM-derived 
macrophages have proposed that microglia express the purinergic receptor P2RY12 and transmembrane protein 119 
(TMEM119)27,28, whereas peripheral PBM-derived macrophages do not36. Similarly, two recent studies also used 
transcriptomics to separate iPSC-derived microglia from other myeloid cells including dendritic cells, monocytes, and 
macrophages29,30. Calcium responses to ADP, which occur via P2RY12 stimulation, are evoked in iPSC-derived 
microglia but not in PBM-derived macrophages28. Other microglial-specific markers that have been shown to be 
expressed on human iPSC-derived microglia, but not PBM-derived macrophages include allograft inflammatory factor 
1 (AIF1, also known as IBA-1), CD11b, CD11c and CX3C chemokine receptor 1 (CX3CR1)28. However, further study 
of these putative markers is required as the expression levels of receptors are likely to be affected by the particular 
cocktail of growth factors or cytokines used. Microglia are capable of expressing a huge repertoire of receptors37,38 
that could influence their phenotype. However, a number of receptors expressed on human adult microglia, including 
P2RY12, CD64 and tyrosine-protein kinase Mer (MERTK) can become down-regulated in microglia upon activation39. 
Therefore any of these proteins in isolation cannot be used as a reliable marker for microglia derived from iPSC cells. 
 
There are also subtle points of overlap between the phenotypes of microglia and those of tissue resident 
macrophages, which depend on their level of activation (and thus overall gene and protein expression). Human 
microglia express C1QA, macrophage colony-stimulating factor 1 receptor (CSF1R) and CD34 genes, as do other 
tissue resident macrophages. Similarly TAM-related genes such as MERTK, vitamin K-dependent protein S (PROS1) 
and growth arrest-specific protein 6 (GAS6), expressed on human macrophages, are also expressed in human 
microglia23. A number of genes regarded as providing a specific ‘signature’ for rodent microglia were recently 
identified; these include Mertk, G-protein coupled receptor 34 (Gpr34), Pros1, C1qa, Gas6 and P2ry1223 . These 
genes were also found to be expressed in human iPSC-derived microglia that were co-cultured with human iPSC-
derived cortical neurons or astrocytes29,31 and to differ from the genes expressed by blood-derived monocytes. 
However, the expression of some of these genes in other human tissue resident macrophages does suggest that a 
microglial-specific signature for human cells is yet to be fully defined, and temporal changes in expression levels and 
an environment-specific context must be taken into account32.  
 As outlined above, transcriptomic studies that have compared mouse iPSC-derived microglia and macrophages have 
been used both to indicate the genes and proteins that it may be important to consider when investigating mouse 
models of disease and to produce a possible genetic signature that is relevant for human microglia23. In addition, a 
recent study that compared gene expression in tissue-resected primary human microglia with that of isolated primary 
mouse microglia, has led to the most comprehensive genetic microglial signature to date40. The authors generated a 
comprehensive picture of the transcriptomic and epigenetic landscapes of the primary isolated microglia to provide a 
detailed overview of human microglial identity. Interestingly, the authors found that there is extensive down-regulation 
of microglia-specific genes when the cells were placed in a tissue culture environment, albeit using undefined serum 
containing medium. The identification of such down-regulation is a significant caveat when trying to develop iPSC-
derived microglia in vitro, and lends further support to the importance of the environmental context that these cells 
are matured in32.  
 
The type of information provided by transcriptomic studies enables fine-tuning of iPSC-microglia methodologies to 
provide a more realistic phenotype. However, it will be imperative that, in the future, such comparisons are attempted 
with fully adult human microglia. Studies that use microglia resected from children have so far provide unparalleled 
data on primary human microglial identity40. However, transcriptomic data from microglia derived from aged 
individuals, however small the cohort, may provide further information on temporal genetic changes, which may be 
relevant to the study of disorders of old age.  
 
Many phenotypic changes are known to occur in microglia with age. Broadly speaking, early postnatal microglia focus 
on synaptic pruning41 and the refinement of CNS connectivity, whereas adult microglia exhibit a surveillant 
phenotype42. How then do the new iPSC-derived microglia compare with these differing microglia phenotypes? To 
date, only one study has directly compared iPSC-derived microglia to both fetal and adult human microglia. This study 
used whole-transcriptome differential gene expression analysis to reveal increased expression of nearly 2000 genes 
in iPSC microglia when compared to foetal microglia, and just over 1000 genes when compared to adult microglia. 
Furthermore, enrichment analysis provided an insight into how iPSC-derived microglia compare to foetal and adult 
microglia30. Three independent studies23,43,44 appeared to show a strong similarity in the differences in gene 
expression levels observed between iPSC-derived microglia and primary human microglia. However the age of the 
primary microglia was not reported28. Thus, further analysis of the published protocols is required to gauge how 
comparable the iPSC-derived cells are to early or late primary microglia. This will not be an easy task due to limited 
availability of primary cell material; however, putting more emphasis on comparing these models to primary microglia 
rather than other myeloid cells should be a priority. 
 
As shown above, a number of iPSC protocols produce good models of macrophage-like cells. The involvement of 
peripheral cellular dysfunction in diseases such as Alzheimer disease should not be ignored45,46,47 and thus it is likely 
that these cells can be used to inform us of the contributions of peripheral changes that can influence central disease. 
In addition macrophages derived from the cells of human patients will express the variants implicated in disease as 
will their central ‘cousins’, the microglial cells. It is critical that both cell types are investigated with regard to disease 
as their responses may be different48 and it may be advantageous to target one over the other when considering 
future therapeutic interventions. 
 In addition to molecular markers, morphological phenotypes are often used to define microglia versus macrophages; 
however, although it is true to say that surveillant microglia in the brain exhibit a highly ramified, motile phenotype 
compared with more bipolar phenotypes observed in macrophage cultures, this rapidly changes upon activation and 
is therefore not a particularly robust marker to distinguish a microglial cell from a macrophage. We would suggest 
that one morphological marker of a microglial phenotype is that of domain sensitivity and contact inhibition (see Fig. 
2). Surveillant microglia very rarely touch each other in vivo or in vitro and only when in an activated state do the cells 
display non-contact inhibition49 (Fig. 2). Furthermore, human macrophages (particularly regulatory macrophages, 
which are akin to human surveillant microglia) in vitro do not display contact-inhibition50,51. We therefore argue that a 
number of markers, including genes, proteins and morphology need to be considered when defining a microglial cell 
and that no single marker will be sufficiently robust.  
 
[H1] Culture types 
 
Many recent studies of human iPSC-derived microglia have tended to focus on two dimensional cultures. This 
approach has both advantages and disadvantages for the user. For example, it is possible to study a cell type without 
the interference of signals from other cell types; however the user is likely to be losing vital information from non-cell 
autonomous signalling. Therefore, many protocols are now focussing on the development of more complex systems, 
through the introduction of the iPSC-derived microglia progenitors to in vivo tissue models or to co-cultures, in a drive 
to produce cells that are more like microglia27,29,30,31,32 . 
 
Co-culturing iPSC-derived microglia with neurons seems to produce microglial like cells with ramifications similar to 
those present in vivo27,31,32, although a ramified motile morphology has also been observed in mono-cultures27,28,30. 
In these cultures there also appears to be a need for the CSF1R ligand IL-34, as well as low levels of GM-CSF or M-
CSF, to be provided in order to maintain microglial survival. This is not unexpected, given that the signals from 
neurons and other glia in the brain have a major influence on the survival and function of microglia and the genes 
and proteins that they express.  
 
If one is to attempt a more complex culture approach, it seems likely that it is important to include as many different 
brain cell types as possible. Indeed, the assumption that culturing iPSC-derived microglia solely with neurons goes 
some way to approaching a more realistic microglial phenotype may be somewhat naïve, given the complexity of 
brain structure and organisation. Furthermore, the relative proportions of each cell type will require consideration, as 
will the specific neuronal cell type used. Indeed, recent work shows that in a complex culture environment there may 
be no requirement of growth factor supplementation32. In this study, iPSC-derived macrophages transferred to a new 
born brain further differentiated into microglia in a manner that relied solely on brain-specific cues32. These culture 
conditions are thus said to recapitulate the development and maturation of microglia in the brain, resulting in highly 
ramified cells expressing a number of microglial markers.  
 
A recent study found that the transference of iPSC-derived human microglia into rat hippocampal co-cultures, 
transgenic mice modelling aspects of Alzheimer disease, or human 3D brain organoids (containing neurons, 
astrocytes and oligodendrocytes) resulted in the production of cells with a more microglial-like phenotype than was 
observed when the iPSC-derived microglia were cultured alone30. Furthermore, culturing iPSC-derived microglia with 
factors such as CX3CL1, CD200 and TGFβ, which are typically produced by other brain cells (such as neurons and 
astrocytes) in the intact brain, produced cells with a transcriptome profile that is highly similar to that of human adult 
and foetal microglia and distinct from monocytes and blood dendritic cells30. 
 
The use of organoid cultures will also allow the influence of microglial risk factors on other cells in the brain, including 
radial glia and neurons, to be examined30,52, as well as the effects of macrophages on peripheral function53. This is 
important because microglia do not exist in isolation in the brain and, as previously mentioned, non-cell autonomous 
effects cannot be observed in two dimensional cultures of isolated cell types. Although each type of cell culture for 
investigating iPSC-microglial and macrophage function (mono-culture, co-culture or organoid) has its own 
advantages, each too comes with its own disadvantages, and these must be factored into models when interpreting 
results.  
 
[H1] The future  
 
There is little doubt that, over the next few years, we will see an increasing refinement in the protocols for the 
production of human iPSC-derived microglia and, hopefully, a consensus on the proteomic and genetic signatures of 
these cells (when compared with tissue-resident macrophages and adult primary microglia) will arise. The production 
of large numbers of macrophage-like and microglial-like cells from iPSCs is a major step towards understanding how 
human microglia and macrophages behave, given that the majority of published studies on microglia have used 
rodent cells. Furthermore, human iPSC-derived microglia hold promise for understanding the functional 
consequences of an increasing number of disease-associated risk factors linked to these cells7. This will be important 
for translational studies and drug screening, and for the development of individualised gene-therapy methodologies54. 
Future research directions could involve the use of human iPSC-generated microglia in transplantation therapies, as 
has been described for rodent models of such diseases as obsessive-compulsive behaviour, CNS lysosomal storage 
diseases and Parkinson disease55,56. 
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Fig. 1. The physiological and pathological functions of microglia. The schematic image illustrates some of the 
physiological functions of microglia that should be considered when using induced pluripotent stem cells to model 
these cells. Microglia contribute to healthy nervous system physiology in several ways. They provide cues and remove 
inappropriate synapses during development and they secrete neurotrophins and cytokines to support and maintain 
neural networks in the mature nervous system42. In addition, they rapidly sense ATP signalling via receptors such as 
P2Y purinoceptor 12 (P2RY12)37,38,50 and migrate to areas of damage, where they proliferate and phagocytose 
apoptotic cells and any other damaged tissue to aid repair. Indeed activation of microglia following CNS damage or 
disease induces a respiratory burst, necessary for an efficient innate immune response38,50. Recent research has 
focussed on the role of lipid signalling in microglia in neurological diseases, including Alzheimer disease (AD). Such 
signalling is mediated by putative membrane associated receptors including triggering receptor expressed on myeloid 
cells 2 (TREM2), mutations in which are genetic risk factors for AD7. Microglia also influence nervous system 
pathology in a number of disorders. They attack the myelin sheath of oligodendrocytes and Schwann cells, 
phagocytose myelin and attempt repair in multiple sclerosis and become reactive in white matter diseases such as 
leukodystrophies. Microglia migrate to and surround amyloid beta plaques in AD, in an attempt either to phagocytose 
this aberrant protein or to corral and contain it to prevent neuronal damage. Microglia also become reactive in 
Huntington disease, dementia with Lewy bodies, Parkinson disease and Creutzfeldt Jakob disease. In the ageing 
brain7,9,10, microglia appear dystrophic and become reactive, senescent and dysfunctional. In addition, their numbers 
are altered during ageing, decreasing in some areas of the brain and increasing in others (see REF.57 for review). 
ADP, adenosine diphosphate; IBA1, allograft inflammatory factor 1; TMEM119, transmembrane protein 119.  
 
Fig. 2. iPSC-derived microglia phenotype characterisation: basic and comprehensive. Current protocols use a 
myriad of assays to assess the phenotypes of iPSC-derived microglia. Basic gene signatures, surface protein 
expression, the expression of cell specific markers, the phagocytosis of microspheres, Eschericia coli or amyloid-β 
(Aβ), and the induction of cytokine release are routinely investigated27,28,29,30,31,32. More comprehensive phenotype 
checking consists of RNA sequencing analysis of the iPSC-derived cells28,29,30. Comparative analyses of the cells’ 
transcriptomic signatures to those recorded from primary microglia data sources will be important to improve capacity 
of iPSC-derived microglia to model their endogenous counterparts. The ability of the cells to generate calcium 
transients and respiratory bursts in response to stimuli are also fundamental microglial phenotypes that should be 
present28,29,30. Integration into iPSC-derived organoids or other tissue sources enables researchers to critically assess 
microglial morphology27,29,30,32. Contact inhibition, including tiling in vitro, is another classical microglial phenotype that 
should also be assessed49. 
 
Table 1: Published methods for the generation of induced pluripotent stem cell-derived macrophages and 
microglia 
Generated 
cell type 
stated*  
Species Tissue and /or 
cellular origin 
Brief methodologies Cellular phenotypes Refs 
ESC-
derived 
microglia 
Mouse ESCs from 
129/Sv Gat 
mice  
Retinoic acid 
induced embryoid 
body differentiation 
ITGAM+ and galactin-3+  58 
ESC-
derived 
microglia 
Mouse ESCs from 
129/Sv CP 
mice; Green ES 
FM260 cells 
Nestin+ selective 
cell expansion, 
growth on laminin 
with bFGF followed 
by GM-CSF 
exposure 
 MHCI+ and /or MHCII+, 
CD40+, CD80+, CD86+, IFN-
γR+  
 Selective accumulation in 
the brain after IV injection. 
 Ramified morphology in vivo 
59 
ESC-
derived 
microglia 
precursor 
Mouse C57BL/6-ATCC 
ESCs 
Growth on laminin 
with FGF2, followed 
by laminin 
withdrawal and 
optional addition of 
GM-CSF 
 IBA1+, ITGAM+, ITGAX+, 
CD45+, CD68+, CD80+, 
CD86+, CD115+, F4/80+, 
CD49d+, CD29+. 
 LPS and/or IFNγ-mediated 
upregulation of pro-
inflammatory cytokines 
 Phagocytosis of 
microsphere bead 
 In vivo engraftment induced 
a classic microglial 
phenotype and morphology 
60,61 
iPSC 
monocyte-
derived 
macrophage 
Human Fibroblast Embryoid body 
formation: addition 
of BMP4, SCF, 
VEGF. Progenitor 
formation: M-CSF, 
IL-3. Maturation: M-
CSF 
 CD45+ and/or CD14+, 
CD16+, CD163+, CD86+, 
MHCII+ 
 Phagocytic and HIV-1 
infectable 
 LPS, IFNγ- and/ or IL4 
mediated altered cytokine 
profiles 
62 
iPSC-
derived 
microglia-
like cell 
Human Fibroblast Embryoid body 
formation using a 
defined in house 
media formulation, 
with M-CSF and IL-
34 
 PU.1+, ITGAM+, IBA1+  
 Phagocytic and highly 
motile 
 Morphologically similar to 
primary microglia 
 P2RY12+, TMEM119+ 
 LPS-mediated pro-
inflammatory cytokine 
induction 
 Comparative transcriptional 
signature to primary 
microglia, enhanced with 
neural co-cultures 
 Integration into organotypic 
neural cultures 
 Dynamically motile and able 
to rapidly respond to cellular 
damage 
27 
iPSC-
derived 
microglia 
Human Fibroblast Progenitor 
formation: 
sequential addition 
of BMP4, bFGF, 
SCF, VEGF, IL-3, 
TPO, M-CSF, 
FLT3L, GM-CSF 
followed by sorting 
for CD14 and/or 
CX3CR1+ 
 CD14+, CD45+, CX3CR1+ 
 highly motile extending 
processes similar to 
microglia in vivo 
 IBA1+, ITGAX+, TMEM119+, 
P2RY12+, ITGAM+, 
CX3CR1+ 
 Deep RNA sequencing 
showed cells clustering with 
human microglia 
28 
progenitors. 
Maturation: IL-34 
and GM-CSF 
 Expression of selected 
microglia 'signature genes' 
 Similar cytokine profile to 
primary microglia  
 Phagocytosis of 
microspheres 
 Calcium transients induced 
upon stimulation. 
iPSC-
derived 
microglia-
like cell 
Human 
and 
mouse 
Cx3cr1Gfp/+ 
mouse 
fibroblasts and 
human cord 
blood-derived 
CD34+ cells 
Progenitor formation 
in hypoxic 
conditions, addition 
of VEGF, BMP4, 
SCF, activin A, 
SCF, FLT3L, IL-3, 
IL-6, GM-CSF, 
BMP4 followed by 
sorting for CD34, 
CD45 and CD43+ 
progenitors. 
Addition to 
astrocytic co-
cultures followed by 
sorting for CD39+ 
iPSC-derived 
microglia. 
Maturation: IL-3, 
GM-CSF and M-
CSF.  
 ITGAM+, IBA1+, HLA-DR+, 
CD45+, TREM2+, CX3CR1+ 
 Microarray data showed 
cells clustering with human 
foetal microglia 
 High expression levels of 
microglial ‘signature' genes 
 Phagocytosis of E.coli 
 LPS-mediated pro-
inflammatory cytokine 
induction 
 Induce ROS upon 
stimulation. 
29 
iPSC-
derived 
microglia-
like cell 
Human Fibroblast or 
PBMC 
Progenitor formation 
in hypoxic 
conditions: D0: 
FGF2, BMP4, 
Activin-A, RI, LiCl; 
D2: FGF2, VEGF; 
D4, 6, and 8: FGF2, 
VEGF, TPO, SCF, 
IL-6, IL-3. CD43+ 
progenitor sort. 
Maturation: M-CSF, 
IL-34, TGFβ-1, + 
1CD200, CX3CL1 
from D35 
CX3CR1+, P2YR12+, MERTK+, 
PROS1+, TGFBR1+, ITGB5+, 
TREM2+; cytokine secretion upon 
inflammatory stimuli (LPS, IFNγ, IL-
1β), migrate and undergo calcium 
transients, and phagocytic capacity 
for CNS substrates including fibrillar 
Aβ); comparative transcriptional 
signature to primary foetal and adult 
microglia that is responsive to a 
neuronal environment (rat primary 
hippocampal cultures and 3D brain 
organoids); cells transplanted into 
transgenic mice or human 
organoids resemble microglia in 
vivo. 
30 
iPSC-
derived 
microglia 
generation 
in neuronal 
co-culture 
Human Fibroblast Embryoid body 
formation: BMP4, 
SCF and VEGF. 
Progenitor 
formation: M-CSF 
and IL-3. 
Maturation: IL-34, 
GM-CSF and 
neuronal co-culture 
 Express P2RY12, GPR34, 
MERTK, C1QA, PROS1, 
GAS6, TMEM119, TREM2 
 Express key surface protein 
markers 
 Develop highly dynamic 
ramifications 
 Phagocytic 
 Become amoeboid and 
cluster upon LPS exposure 
 Release microglia-relevant 
cytokines, and upregulate 
homeostatic function 
pathways 
 Promote a more anti-
inflammatory response than 
monocultures  
31 
iPSC-
derived 
microglia 
generation 
in neuronal 
co-culture 
Human 
and 
Mouse 
Human or 
mouse 
fibroblasts 
Progenitor formation 
in hypoxic 
conditions with 
addition of BMP4, 
VEGF, CHIR99021, 
FGF2, SCF, DKK1, 
IL-6, IL-3 followed 
by normoxic 
conditions with 
FGF2, SCF, IL-6, IL-
3. Sorting for CD45, 
ITGAM,CD163, 
CD14 and CX3CR1+ 
'hiMacs' for addition 
to neuronal co-
cultures  
 hiMacs: CD45+, CD14+, 
ITGAM+ CD163+, CX3CR1+;  
 hiMicro: IBA1+; CX3CR1+ 
 Phagocytosis of beads and 
Aβ. 
32 
  
The table provides a brief overview of the current published methods of early iPSC-myeloid cell generation and 
subsequent techniques for the establishment of iPSC derived macrophages and microglia. Please refer to the citations 
within for full comprehensive methodologies. * If murine/human protocols are both described: methodologies and 
derived cell phenotypes are described for the human protocol. Aβ, amyloid-beta; bFGF, basic fibroblast growth factor; 
BMP4, bone morphogenetic protein 4; CHIR99021, glycogen synthase kinase 3 inhibitor; CSF1, colony-stimulating 
factor 1; CX3CR1, CX3C chemokine receptor 1; DKK1, dickkopf-related protein 1; ESC, embryonic stem cell; FGF2, 
fibroblast growth factor 2; FLT3L, FMS-like tyrosine kinase 3 ligand; GAS6, growth arrest-specific protein 6; GM-CSF, 
granulocyte macrophage colony-stimulating factor; GPR34, probable G-protein coupled receptor 34; hiMacs, (human 
iPSC-derived primitive macrophages); hiMicro, (human iPSC-derived Microglia-like cells) HIV-1; human 
immunodeficiency virus 1; HLA-DR, human leukocyte antigen – antigen D related; IBA1, allograft inflammatory factor 
1; IFN-γ, interferon-γ; IFN-γR, interferon-γ receptor; IL-3, interleukin-3; iPSC, induced pluripotent stem cell; ITGAM, 
integrin alpha-M; ITGAX, integrin alpha-X; LPS, lipopolysaccharide; M-CSF, macrophage/monocyte colony-stimulating 
factor; MERTK, tyrosine-protein kinase Mer; MHC1, major histocompatibility complex class I molecules; P2RY12, P2Y 
purinoceptor 12; PROS1, vitamin K-dependent protein S; ROS, reactive oxygen species; SCF, stem cell factor; 
TMEM119, transmembrane protein 119; TPO, thrombopoetin; TREM2, triggering receptor expressed on myeloid cells 
2 ; VEGF, vascular endothelial growth factor; 
 
